Author

Cecilio Santander Vaquero 1

1 Hospital Universitario de La Princesa,Madrid,Spain

Budesonide orodispersible tablets are superior to maintain and even further improve quality of life in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Christoph Schlag, Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

Budesonide orodispersible tablets are superior to maintain combined clinical and histological remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Alex Straumann, Alfredo J. Lucendo, Stephan Miehlke, Michael Vieth, Christoph Schlag, Luc Biedermann, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Stefan Schubert, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen

ROLE OF HIGH RESOLUTION MANOMETRY IN THE DIAGNOSTIC AND THERAPEUTIC APPROACH OF POST FUNDOPLICATION DYSPHAGIA

Armando Peixoto, Rui Morais, Aitor Lanas Gimeno, Teresa Pérez Fernández, Sergio Casabona Francés, Guilherme Macedo, Cecilio Santander Vaquero

A novel budesonide orodispersible tablet formulation is highly effective to maintain endoscopic inflammatory remission and even complete endoscopic remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

Luc Biedermann, Alfredo J. Lucendo, Stephan Miehlke, Christoph Schlag, Cecilio Santander Vaquero, Constanza Ciriza De Los Ríos, Dirk Hartmann, Ahmed Madisch, Petr Hruz, Jamal Hayat, Ulrike von Arnim, Arjan Bredenoord, Ralph Müller, Roland Greinwald, Alain Schoepfer, Stephen E. Attwood, Alex Straumann

A novel oral budesonide formulation is highly effective for induction of remission in patients with active eosinophilic esophagitis: Results from the 6-weeks open-label treatment phase of EOS-2 trial

Alfredo J. Lucendo, Christoph Schlag, Stephan Miehlke, Luc Biedermann, Cecilio Santander Vaquero, Dirk Hartmann, Jamal Hayat, Petr Hruz, Constanza Ciriza De Los Ríos, Arjan Bredenoord, Michael Vieth, Ralph Müller, Roland Greinwald, Alex Straumann

Item 1 - 5 / 5
1